Advertisement

Picture Berlin Partner Top News Noah Labs Raises $3m AI Telemonitoring 650x100px
Organisation › Details

Pentixapharm Holding AG (FSE Prime Standard: PTP)

Pentixapharm Holding AG was founded in 2024 to incorporate all shares held by Eckert & Ziegler SE in Pentixapharm AG, based in Würzburg, following the spin-off resolved by the Annual General Meetings of Eckert & Ziegler SE and Pentixapharm Holding AG on June 26, 2024. It is intended to list Pentixapharm Holding AG on the Prime Standard of the Frankfurt Stock Exchange. Pentixapharm AG is a clinical-stage radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Pentixapharm’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Clinical studies for both compounds have already commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. Additionally, PentixaFor is being developed as a diagnostic tool for primary aldosteronism (PA), a major cause of hypertension. Pentixapharm is currently preparing a US-centric Phase III registration study with PentixaFor in PA that will start in 2025. *

 

Period Start 2024-10-02 splitoff
  Group Pentixapharm (Group)
  Today Pentixapharm (Group)
  Predecessor Eckert & Ziegler (Group)
Products Industry RADIOPHARMACEUTICAL (RPT)
  Industry 2 diagnostics (medical/biological)
Persons Person Bouterfa, Hakim (Pentixapharm 202410– CEO before Eckert & Ziegler 202306 CMO + OctreoPharm Sciences GmbH)
  Person 2 Eckert, Andreas (Eckert & Ziegler)
     
Region Region Berlin
  Country Germany
  Street 10 Robert-Rössle-Str.
Campus Berlin-Buch
  City 13125 Berlin
  Tel +49-30-9489-2600
    Address record changed: 2024-09-25
     
Basic data Employees n. a.
     
    * Document for »About Section«: Pentixapharm Holding AG. (9/23/24). "Press Release: Pentixapharm Holding AG Sets Price Range for Planned IPO [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg.
     
   
Record changed: 2024-09-25

Advertisement

Picture biomindz Mainz Biomed LSG Colorectal Cancer Screening 650x200px

More documents for Pentixapharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture biomindz Brand LSG Mainz Place to Biotech 650x300px




» top